Literature DB >> 28781777

A pharmacokinetic study of diclofenac sodium in rats.

Jing Yuan1, He Ma1, Nannan Cen1, Ai Zhou1, Hengxun Tao1.   

Abstract

The aim of the present study was to examine the pharmacokinetics of a single intravenous injection (i.v.) and oral administration (p.o.) of diclofenac sodium (DIC) in Sprague-Dawley (SD) rats. Twelve male SD rats were divided into 2 groups (n=6 per group); one group was injected intravenously with 2 mg/kg DIC, whereas the other group was lavaged with 2 mg/kg DIC. Blood samples were collected prior to DIC delivery (0 h) and 0.033, 0.083, 0.167, 0.25, 0.5, 1, 2, 4, 6, and 8 h post-administration. Blood plasma samples were analyzed using liquid chromatography-mass spectrometry (LC-MS/MS) following pretreatment to induce protein precipitation. Pharmacokinetics software was applied to calculate relevant pharmacokinetic parameters using a non-compartmental model. Following i.v. administration of DIC, the terminal elimination rate constant (λz), apparent terminal elimination half-life (t½), area under the concentration-time curve from time 0 extrapolated to infinity (AUC0-∞), clearance (CL), apparent volume of distribution (Vz), mean residence time (MRT), and apparent volume of distribution at steady state (Vss) were 0.57±0.05 l/h, 1.22±0.11 h, 3356±238 h × ng/ml, 0.60±0.04 l/h, 1.05±0.10 l, 1.05±0.07 h and 0.63±0.07 l, respectively. Following p.o. administration of DIC, the λz, t½, Cmax, tmax, AUC0-∞, CL, Vz, MRT were: 0.63±0.12 l/h, 1.12±0.18 h, 1272±112 ng/ml, 0.19±0.04 h, 2501±303 h × ng/ml, 0.81±0.10 l/h, 1.29±0.12 l, and 2.70±0.18 h, respectively. The pharmacokinetic parameters of i.v. and p.o. DIC in rats show that the drug is rapidly absorbed, distributed, and eliminated.

Entities:  

Keywords:  diclofenac sodium; intravenous injection; oral medication; pharmacokinetics; rat

Year:  2017        PMID: 28781777      PMCID: PMC5526189          DOI: 10.3892/br.2017.942

Source DB:  PubMed          Journal:  Biomed Rep        ISSN: 2049-9434


  14 in total

1.  Bioanalytical method validation--a revisit with a decade of progress.

Authors:  V P Shah; K K Midha; J W Findlay; H M Hill; J D Hulse; I J McGilveray; G McKay; K J Miller; R N Patnaik; M L Powell; A Tonelli; C T Viswanathan; A Yacobi
Journal:  Pharm Res       Date:  2000-12       Impact factor: 4.200

2.  Pharmacokinetics of diclofenac and its interaction with enrofloxacin in sheep.

Authors:  Anu Rahal; Amit Kumar; A H Ahmad; J K Malik
Journal:  Res Vet Sci       Date:  2007-08-10       Impact factor: 2.534

3.  Precision, accuracy, and data acceptance criteria in biopharmaceutical analysis.

Authors:  H T Karnes; C March
Journal:  Pharm Res       Date:  1993-10       Impact factor: 4.200

4.  Pharmacokinetics of a new diclofenac sodium formulation developed for subcutaneous and intramuscular administration.

Authors:  Markus Zeitlinger; Antonio Rusca; Alhan Z Oraha; Barbara Gugliotta; Markus Müller; Murray P Ducharme
Journal:  Int J Clin Pharmacol Ther       Date:  2012-06       Impact factor: 1.366

5.  Diclofenac potassium 25 mg liquid capsules: earlier and higher exposure to diclofenac. A fasted, single-dose, comparative bioavailability study vs. diclofenac potassium 2 x 12.5 mg tablets.

Authors:  Marianna Armogida; Morris Gold
Journal:  Int J Clin Pharmacol Ther       Date:  2012-06       Impact factor: 1.366

6.  Disposition and enterohepatic circulation of diclofenac in dogs.

Authors:  T Tsuchiya; M Terakawa; K Ishibashi; H Noguchi; R Kato
Journal:  Arzneimittelforschung       Date:  1980

7.  Plasma and synovial fluid concentrations of diclofenac sodium and its major hydroxylated metabolites during long-term treatment of rheumatoid arthritis.

Authors:  P D Fowler; M F Shadforth; P R Crook; V A John
Journal:  Eur J Clin Pharmacol       Date:  1983       Impact factor: 2.953

Review 8.  Diclofenac sodium. A reappraisal of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy.

Authors:  P A Todd; E M Sorkin
Journal:  Drugs       Date:  1988-03       Impact factor: 9.546

9.  Effect of Resveratrol Treatment on the Pharmacokinetics of Diclofenac in Healthy Human Volunteers.

Authors:  Satish Kumar Bedada; Narsimha Reddy Yellu; Prasad Neerati
Journal:  Phytother Res       Date:  2015-12-03       Impact factor: 5.878

10.  Comparative bioavailability and tolerability of single and multiple doses of 2 diclofenac sodium sustained-release tablet formulations in fasting, healthy chinese male volunteers.

Authors:  Xue-Jia Zhai; Ye Yu; Fen Chen; Yong-Ning Lu
Journal:  Curr Ther Res Clin Exp       Date:  2013-12
View more
  6 in total

1.  Dose-dependency of the cardiovascular risks of non-steroidal anti-inflammatory drugs.

Authors:  Surur Ali Ahmed; Hanan Al-Lawati; Fakhreddin Jamali
Journal:  Inflammopharmacology       Date:  2019-07-29       Impact factor: 5.093

2.  Modulation of Rat Hepatic CYP1A and 2C Activity by Honokiol and Magnolol: Differential Effects on Phenacetin and Diclofenac Pharmacokinetics In Vivo.

Authors:  Sang-Bum Kim; Kyu-Sang Kim; Heon-Min Ryu; Seong-Ho Hong; Bo-Kyoung Kim; Dae-Duk Kim; Jin Woo Park; In-Soo Yoon
Journal:  Molecules       Date:  2018-06-17       Impact factor: 4.411

3.  Antinociceptive and anti-inflammatory effects of N-acetylcysteine and verapamil in Wistar rats.

Authors:  Ahmed Abdullah Elberry; Souty Mouner Zaky Sharkawi; Mariam Rofaiel Wahba
Journal:  Korean J Pain       Date:  2019-10-01

4.  Modulation of the In Vivo Inflammatory Response by Pro- Versus Anti-Inflammatory Intervertebral Disc Treatments.

Authors:  Carla Cunha; Graciosa Q Teixeira; Cláudia Ribeiro-Machado; Catarina L Pereira; Joana R Ferreira; Maria Molinos; Susana G Santos; Mário A Barbosa; Raquel M Goncalves
Journal:  Int J Mol Sci       Date:  2020-03-03       Impact factor: 5.923

5.  Diclofenac Concentrations in Post-Mortem Specimens-Distribution, Case Reports, and Validated Method (UHPLC-QqQ-MS/MS) for Its Determination.

Authors:  Paweł Szpot; Olga Wachełko; Marcin Zawadzki
Journal:  Toxics       Date:  2022-07-26

6.  Antinociceptive Interaction and Pharmacokinetics of the Combination Treatments of Methyleugenol Plus Diclofenac or Ketorolac.

Authors:  Héctor Isaac Rocha-González; María Elena Sánchez-Mendoza; Leticia Cruz-Antonio; Francisco Javier Flores-Murrieta; Xochilt Itzel Cornelio-Huerta; Jesús Arrieta
Journal:  Molecules       Date:  2020-11-03       Impact factor: 4.411

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.